logo

For the Inventor, By the Inventor

La Jolla, CA, United States of America

Angelica N Sanabria

This inventor holds 10 USPTO granted patents and 4 published patent applications. Top assignees: Inhibrx Biosciences, Inc., Oxford Finance LLC, Inhibrx, Inc.. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Angelica N Sanabria. Retrieved from https://idiyas.com/inventor/angelica-n-sanabria

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

% Patents Active = 100.0

Average Co-Inventor Count = 6.4

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:

goldMedal5 out of 11 
 
Inhibrx Biosciences, Inc.
 patents
silverMedal4 out of 10 
 
Oxford Finance LLC
 patents
bronzeMedal3 out of 30 
 
Inhibrx, Inc.
 patents
4. 1 out of 1,484 
 
Regeneron Pharmaceuticals, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...
10 patents (USPTO):Explore Patents
1. 12590169 - 5T4 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF (2026-03-31),
2. 12552855 - CD33 TARGETED IMMUNOTHERAPIES (2026-02-17),
3. 12421315 - CLL-1 targeted immunotherapies (2025-09-23),
4. 12365728 - DLL3 single domain antibodies and therapeutic compositions thereof (2025-07-22),
5. 12297271 - PD-1 single domain antibodies and therapeutic compositions thereof (2025-05-13),
6. 12084502 - CD33-binding polypeptides and uses thereof (2024-09-10),
7. 12043667 - CLEC12a binding polypeptides and uses thereof (2024-07-23),
8. 11945869 - PD-1 single domain antibodies and therapeutic compositions thereof (2024-04-02),
9. 11560428 - CD33-binding polypeptides and uses thereof (2023-01-24),
10. 11208485 - PD-1 single domain antibodies and therapeutic compositions thereof (2021-12-28),

Title: Innovations and Contributions of Angelica N Sanabria

Introduction

Angelica N Sanabria is a prominent inventor based in La Jolla, California. She has made significant contributions to the field of immunotherapy, holding a total of eight patents. Her work focuses on developing targeted therapies for various diseases, including cancer.

Latest Patents

Among her latest patents is the development of CLL-1 targeted immunotherapies. This patent provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies aimed at treating, preventing, or ameliorating symptoms of cancer, infectious diseases, autoimmune diseases, inflammatory diseases, and immunodeficiencies. Another notable patent involves DLL3 single domain antibodies and therapeutic compositions. This patent includes binding polypeptides that specifically bind DLL3, as well as fusion proteins and pharmaceutical compositions for treating diseases such as cancer.

Career Highlights

Angelica has worked with notable companies in the biotechnology sector, including Inhibrx Biosciences, Inc. and Inhibrx, Inc. Her innovative work has positioned her as a key figure in the development of advanced therapeutic solutions.

Collaborations

Throughout her career, Angelica has collaborated with esteemed colleagues, including John C Timmer and Brendan P Eckelman. These partnerships have further enhanced her research and development efforts in the field of immunotherapy.

Conclusion

Angelica N Sanabria's contributions to immunotherapy through her patents and collaborations highlight her role as an influential inventor. Her work continues to pave the way for advancements in treating complex diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…